Stoke Therapeutics (NASDAQ:STOK) Insider Sells $59,738.68 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,006 shares of Stoke Therapeutics stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $29.78, for a total transaction of $59,738.68. Following the completion of the transaction, the insider directly owned 17,170 shares of the company’s stock, valued at $511,322.60. This trade represents a 10.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Friday, December 5th, Barry Ticho sold 3,662 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $114,767.08.
• On Thursday, December 4th, Barry Ticho sold 1,696 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.87, for a total transaction of $52,355.52.
• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $61,729.10.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.72, for a total value of $152,545.32.

Stoke Therapeutics Trading Down 0.6%

Stoke Therapeutics stock opened at $30.87 on Friday. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $38.69. The stock has a fifty day simple moving average of $29.03 and a two-hundred day simple moving average of $19.83. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 46.07 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. On average, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Generali Investments Management Co LLC bought a new position in Stoke Therapeutics in the third quarter worth approximately $41,000. BNP Paribas Financial Markets increased its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. AlphaQuest LLC bought a new position in Stoke Therapeutics in the 1st quarter worth $72,000. Finally, US Bancorp DE lifted its position in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after purchasing an additional 11,108 shares in the last quarter.

Wall Street Analysts Forecast Growth

STOK has been the topic of several research analyst reports. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Monday. Finally, JPMorgan Chase & Co. raised their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Stoke Therapeutics has an average rating of “Buy” and an average price target of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.